Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that while the SNP rs6152 is strongly associated with androgenetic alopecia, the GGN triplet repeat is not, suggesting the causative variant is likely a non-coding one.

The researchers reported that the SAGI PGP procedure resulted in excess weight loss of over 90% in the first year and normalized blood sugar levels without medication among diabetic patients by the first month post-operation.

This study found that a standardized PRP application protocol was effective as a coadjuvant therapy in most patients with androgenetic alopecia who did not respond to minoxidil or finasteride, based on improvements in Ebling's scale.

This study found that platelet-rich plasma significantly increased hair density and anagen hair proportions in androgenetic alopecia patients, suggesting potential as an adjuvant therapy.

This study found that the loss of ASLNC168501 accelerates hair follicle stem cell dysfunction in androgenetic alopecia through activation of the AR/miR-128-3p/IGF-1 pathway, suggesting that restoring ASLNC168501 could be a promising therapeutic strategy for hair regeneration.

This study provides evidence that five Hyp-O-GALT genes are crucial for AGP galactosylation and that AGP glycans are vital for various aspects of plant growth and development.

PRP treatment increased hair density, especially in men and younger patients with AGA.

Combining PRP with other treatments can improve hair loss outcomes.

This study found that plasma rich in growth factors showed promising results for increasing hair number and thickness in androgenic alopecia patients, with better outcomes after multiple injections.

CGF-PF may improve hair loss treatment by targeting hair follicle stem cells more effectively.

This study found that autologous non-activated platelet-rich plasma (A-PRP) was effective and safe for treating androgenetic alopecia, showing long-term improvement in hair density, thickness, and count.

This review outlines platelet-rich plasma practices for androgenetic alopecia at a large academic center and highlights the importance of standardizing PRP protocols to improve treatment outcomes, but it reports no new clinical results.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study found that serum GPER-1 levels were significantly higher in patients with androgenetic alopecia compared to healthy controls, suggesting a potential role in the condition's pathogenesis, independent of gender.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.

PGD2 stops hair growth and is higher in bald men with AGA.

This analysis suggests that platelet-rich plasma therapy may be promising for treating androgenetic alopecia, but further controlled trials with standardized measures are needed to confirm its efficacy.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

This review discusses recent clinical trials on the use of platelet rich plasma for treating androgenetic alopecia and reports mixed findings on its effectiveness compared to standard treatments.

In this study, iL-PRF injections produced significantly better clinical scores for androgenetic alopecia patients compared to controls, especially in those with more severe baseline conditions.

This study found that combining PRP with concentrated growth factors was more effective than PRP alone in promoting hair regrowth for patients with androgenetic alopecia.

This article discusses the potential role and mechanisms of platelet-rich fibrin therapies in androgenetic alopecia management, exploring their possible benefits over existing treatments but reports no new clinical results.

In this study, PRPF treatment was more effective than PRP alone in improving hair count and hair quality in androgenetic alopecia patients, with PRPF showing significant improvements in various hair growth parameters and having no statistical differences observed in the placebo group.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This review discusses the current literature on platelet rich plasma injections for androgenetic alopecia, noting that while some studies report positive outcomes, they often suffer from methodological weaknesses and inconsistent results.

In this study, no significant change in androgen receptor gene expression was found in females with recurrent spontaneous abortion, but a mutant genotype may offer some protection against the condition.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

In this study, researchers found that pigs with genetically disrupted ANTXR1 were resistant to Senecavirus A infection, showing no clinical symptoms, and provided a model for human GAPO syndrome, while confirming ANTXR1 as a receptor for the virus.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.